Literature DB >> 19454491

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.

Miroslav Djokic1, Elisabet Björklund, Elisabeth Blennow, Joanna Mazur, Stefan Söderhäll, Anna Porwit.   

Abstract

We evaluated CD123 expression in 95 pediatric and 24 adult ALL patients and compared the results with the CD123 expression in normal B-cell precursors. Early B-cell precursors were negative while intermediate precursors and mature B cells showed weak CD123 expression. Leukemic blasts in 31% of precursor-B ALL samples exhibited strong expression of CD123, 61% had moderate CD123 expression and 8% were negative; 81.5% of ALL with hyperdiploid karyotype (>/= 52 chromosomes) showed strong CD123 overexpression. In contrast, cases with ETV6/RUNX1 rearrangement had weak CD123 expression. Our study suggests that overexpression of CD123 is an aberrant phenotype present in a subset of precursor-B ALL with hyperdiploid genotype, and represents an additional marker of good prognosis in pediatric precursor-B ALL. Moreover, aberrant CD123 expression in ALL is a good marker for monitoring of minimal residual disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454491      PMCID: PMC2704314          DOI: 10.3324/haematol.2008.000299

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  17 in total

1.  Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.

Authors:  P Lúcio; A Parreira; M W van den Beemd; E G van Lochem; E R van Wering; E Baars; A Porwit-MacDonald; E Bjorklund; G Gaipa; A Biondi; A Orfao; G Janossy; J J van Dongen; J F San Miguel
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

Review 2.  Cytokine receptors and signal transduction.

Authors:  A Miyajima; T Kitamura; N Harada; T Yokota; K Arai
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy.

Authors:  L Lhermitte; A de Labarthe; C Dupret; H Lapillonne; C Millien; J Landman-Parker; O Hermine; A Baruchel; F Sigaux; E Macintyre; V Asnafi
Journal:  Leukemia       Date:  2006-08-10       Impact factor: 11.528

4.  Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors.

Authors:  Ugo Testa; Giovanni F Torelli; Roberta Riccioni; Andrea Onetti Muta; Stefania Militi; Luciana Annino; Gualtiero Mariani; Anna Guarini; Sabina Chiaretti; Jerome Ritz; Franco Mandelli; Cesare Peschle; Robin Foa
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  CD40 ligand upregulates expression of the IL-3 receptor and stimulates proliferation of B-lineage acute lymphoblastic leukemia cells in the presence of IL-3.

Authors:  M Zhou; L Gu; J Holden; A M Yeager; H W Findley
Journal:  Leukemia       Date:  2000-03       Impact factor: 11.528

6.  A cytokine receptor gene cluster in the X-Y pseudoautosomal region?

Authors:  E Kremer; E Baker; R J D'Andrea; R Slim; H Phillips; P A Moretti; A F Lopez; C Petit; M A Vadas; G R Sutherland
Journal:  Blood       Date:  1993-07-01       Impact factor: 22.113

Review 7.  Interleukin-3 receptor in acute leukemia.

Authors:  U Testa; R Riccioni; D Diverio; A Rossini; F Lo Coco; C Peschle
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

8.  Mutational analysis of the alpha subunit of the human interleukin-3 receptor.

Authors:  A P Rapoport; S Luhowskyj; P Doshi; J F DiPersio
Journal:  Blood       Date:  1996-01-01       Impact factor: 22.113

9.  Leukemic B-cell precursors express functional receptors for human interleukin-3.

Authors:  F M Uckun; T G Gesner; C W Song; D E Myers; A Mufson
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

10.  Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.

Authors:  E Björklund; J Mazur; S Söderhäll; A Porwit-MacDonald
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

View more
  28 in total

1.  New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Christopher Clark; Laura Key; Peixin Liu; Mohammad Mehrpooya; Patricia Stow; Xiaoping Su; Sheila Shurtleff; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

2.  Immuno-phenotypes and prognosis of acute leukemia in elderly patients.

Authors:  Fanmei Ge; Baoli Li; Xuemei Gao; Yu Ren; Hui Liu; Baoxiong Su; Yuhong Liu; Huiqin Cao
Journal:  Int J Clin Exp Med       Date:  2014-10-15

3.  Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.

Authors:  Wen Du; Juan Li; Wei Liu; Yanli He; Junxia Yao; Yu Liu; Jun Lin; Jine Zheng
Journal:  Tumour Biol       Date:  2015-10-16

Review 4.  Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Authors:  Minas P Economides; David Rizzieri; Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

5.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Authors:  Prisca Theunissen; Ester Mejstrikova; Lukasz Sedek; Alita J van der Sluijs-Gelling; Giuseppe Gaipa; Marius Bartels; Elaine Sobral da Costa; Michaela Kotrová; Michaela Novakova; Edwin Sonneveld; Chiara Buracchi; Paola Bonaccorso; Elen Oliveira; Jeroen G Te Marvelde; Tomasz Szczepanski; Ludovic Lhermitte; Ondrej Hrusak; Quentin Lecrevisse; Georgiana Emilia Grigore; Eva Froňková; Jan Trka; Monika Brüggemann; Alberto Orfao; Jacques J M van Dongen; Vincent H J van der Velden
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

Review 6.  Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Authors:  Elaine Coustan-Smith; Dario Campana
Journal:  Best Pract Res Clin Haematol       Date:  2010-10-28       Impact factor: 3.020

7.  Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China.

Authors:  Xiaoming Liu; Yao Zou; Li Zhang; Xiaojuan Chen; Wenyu Yang; Ye Guo; Yumei Chen; Yingchi Zhang; Xiaofan Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-02       Impact factor: 4.553

8.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

9.  Recent advances in bone marrow biopsy pathology.

Authors:  Jon van der Walt
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

10.  Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.

Authors:  Ibrahim Aldoss; Mary Clark; Joo Y Song; Vinod Pullarkat
Journal:  Hum Vaccin Immunother       Date:  2020-07-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.